Court ruling gives hope to Alzheimer's sufferers
Legal World
More patients could get access to Alzheimer's drugs on the NHS after two drug companies won a landmark court victory.
The Court of Appeal ruled that the National Institute for Health and Clinical Excellence (NICE) -- the body that controls the prescription of new drugs -- must be more transparent about how it calculates the cost-effectiveness of new treatments.
In a ruling delivered Thursday, the judges found the process by which NICE decided to restrict Alzheimer's drug Aricept to patients with a moderate version of the degenerative brain disease "was procedurally unfair".
They added that NICE should release a full version of the cost-effectiveness model used to produce guidance for the drugs.
NICE had decided in 2004 that the drugs, which cost about £2.50 a day and slow down the progress of the disease, are not cost-effective for patients in the early stages of Alzheimer's. This decision was upheld by a court in 2007.
Drug companies Eisai Ltd and Pfizer Ltd, which challenged the NICE decision, welcomed the Court of Appeal's ruling, saying it brought new hope for Alzheimer's patients.
Nick Burgin, managing director of Eisai, said: "We believe that this decision represents a victory for common sense. As soon as we have reviewed their cost-effectiveness calculations we will submit any new findings to NICE.
"We hope that this action will ultimately restore access to anti-dementia medicines for those patients at the mild stages of Alzheimer's disease."
NICE chief executive Andrew Dillon said: "We will be considering very carefully the findings and the implications for the time it takes us to provide advice to patients and the NHS on the use of new treatments.
"It is important to recognise that we have not been asked to amend or withdraw our current guidance on the use of these drugs to treat Alzheimer's disease: the drugs continue to be recommended only for people with moderate Alzheimer's disease."
Neil Hunt, chief executive of the Alzheimer's Society said: "Today's decision is a damning indictment of the fundamentally flawed process used by NICE to deny people with Alzheimer's disease access to drug treatments."
Alzheimer's disease is the most common form of dementia, affecting around 417,000 people in the UK.
Related listings
-
Intl. Court unseals warrant for Congo militia leader
Legal World 04/29/2008The International Criminal Court has published an arrest warrant for a Congo militia leader wanted for allegedly using child soldiers.The court says Bosco Ntaganda conscripted child soldiers to fight in the Ituri region of eastern Congo from July 200...
-
Chinese Police Clash With Tibet Protesters
Legal World 03/14/2008Violent protests erupted Friday in a busy market area of Lhasa, the Tibetan capital, as Buddhist monks and other ethnic Tibetans clashed with Chinese security forces. Witnesses say the protesters burned shops, cars, military vehicles and at least one...
-
German Court Upholds Incest Law
Legal World 03/13/2008Germany's highest court has upheld a law that makes incest a criminal offense, rejecting an appeal by a man who was sentenced to prison after fathering four children with his sister.The Federal Constitutional Court said Thursday it has ruled that the...
New York Commercial Litigation Law Firm - Woods Lonergan PLLC
Founded in 1993 by Managing Partner James F. Woods, Woods Lonergan PLLC has built a strong reputation as a resourceful and industrious firm that provides clients with clear, concise, and straightforward answers to their most challenging legal issues. Partner Lawrence R. Lonergan, who joined the firm in 2008, has been a friend and colleague to Mr. Woods for over 40 years and shares the same business philosophy. Woods Lonergan PLLC’s collective experience and expertise enables the firm to expeditiously and effectively analyze the increasing challenges clients face in an evolving business and legal world, in many instances, avoiding unnecessary time and expense to our clients. Our mission is simple: provide cutting-edge expertise and sound advice in select areas of the law for corporate and business clients. We thrive on providing each client with personalized attention, forceful representation, and a collaborative team effort that embraces collective knowledge.